Am J Transplant, Volume 5, Suppl 3 Archives - Page 94 of 170 - ATC Abstracts

2015 American Transplant Congress
Donor Specific Tolerance Can Be Induced by Donor Bone Marrow Transfer With Activation of Invariant Naturel Killer T Cells
S. Miyairi,¹ T. Hirai,¹ R. Shibahara,¹ K. Omoto,¹ S. Nunoda,² K. Yamazaki,² Y. Ishii,³ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan; ²Cardiovascular Surgery, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan; ³Laboratory of Vaccine Design, RIKEN IMS-RCAI, Yokohama, Japan.
It has been reported that liposomal formulation of a-galactosylceramide(lipo-aGC) could induce antigen specific regulatory T cells (Treg) in vivo when administered with particular antigens. We…
2015 American Transplant Congress
Cell Type of the Tolerizing Inoculum Plays a Role in the Formation of of Molecular Chimerism in Murine Neonatal Tolerance
X. Wang,¹ H. Mewhort,¹ S. Wang,¹ S. Tollenaar,¹ K. Tao,¹ L. West.^1,2,3
¹Department of Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Department of Surgery, University of Alberta, Edmonton, AB, Canada; ³Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada.
Background: Heart transplantation is a lifesaving measure for many infants with severe congenital heart diseases. The acceptance of cardiac allografts without immunosuppression, or operational tolerance,…
2015 American Transplant Congress
Everolimus With Low Dose Tacrolimus in Intestinal Transplantation
T. Beduschi, J. Garcia, J. Lugo-Baruqui, J. Fan, S. Nishida, J. Jebrock, A. Tekin, G. Selvaggi, P. Ruiz, R. Vianna.
Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL.
Introduction: Renal dysfunction is a well-known complication after organ transplant given immunosuppression (ISP) with calcineurin inhibitors. This is especially true after intestinal transplant (ITx) given…
2015 American Transplant Congress
Does Prophylaxis Strategy Matter? CMV Reactivation in Moderate Risk (R+) Heart Transplant Recipients
E. Liu, C. Doligalski.
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: CMV is a significant complication in heart transplant recipients (HTR). Little evidence exists to guide prophylaxis in moderate risk (R+) patients.Methods: An IRB-approved review…
2015 American Transplant Congress
Assessment of Renal Function in Kidney Transplant Recipients Through Therapeutic Drug Monitoring of Vancomycin
A. Thamer, N. Elias, C. Varughese, T. Gift, J. Fishman, S. Shao.
Massachusetts General Hospital, Boston, MA.
Background: Determining the dose of renally eliminated drugs such as vancomycin in kidney transplant recipients is often challenging due to unclear tools to assess renal…
2015 American Transplant Congress
Living and Dead Mesenchymal Stem Cells Induce an Immunosuppressive Response in an Experimental Sepsis Model
F. Luk,¹ M. Roemeling-van Rhijn,¹ S. de Witte,¹ S. Korevaar,¹ R. de Bruin,² M. Betjes,¹ C. Baan,¹ M. Hoogduijn.¹
¹Nephrology and Transplantation, Dept. of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; ²Transplant Surgery, Dept. of Surgery, Erasmus Medical Center, Rotterdam, Netherlands.
There is evolving interest in the use of mesenchymal stem cells (MSC) as a cell therapeutic agent after solid organ transplantation. The nature of the…
2015 American Transplant Congress
Bioengineering Liver Allografts through Organ Scaffold Recellularization
J. Woodall, J. Langford, C. Klassen, J. Harrison, D. Parsell, U. Dhru, R. Barth, J. LaMattina.
University of Maryland School of Medicine, Baltimore.
Bioengineering livers using organ scaffolds offers an approach to increasing allograft availability for end stage liver disease. Recellularized liver scaffolds will require multiple differentiated cell…
2015 American Transplant Congress
Conversion to Belatacept After Kidney Transplantation Does Not Alter Immunophenotype
M. Matz,¹ K. Fabritius,¹ C. Lorkowski,¹ J. Liu,¹ S. Brakemeier,¹ N. Unterwalder,² H.-H. Neumayer,¹ K. Budde.¹
¹University Medicine Charité, Berlin, Germany; ²Labor Berlin GmbH, Berlin, Germany.
Belatacept offers a new option for renal allograft recipients who are suffering from side effects of calcineurin inhibitor or mTOR. Such a conversion may result…
2015 American Transplant Congress
Transplantation of Kidneys from Donors With Acute Renal Failure: Five-Year Results from Double Center Experience
C. Ramirez,^1,2 A. Safra,¹ A. Shah,^1,2 C. Doria,¹ W. Maley,¹ A. Frank,¹ C. Gorn,¹ L. Lerner.²
¹Department of Surgery, Division of Transplantation, Thomas Jefferson University Hospital, Philadelphia, PA; ²Department of Kidney Transplantation, Lankenau Medical Center, Wynnewood, PA.
Background: Transplantation of kidneys from deceased donors with acute renal failure (ARF) has been described and represents an underutilized source of renal grafts. We reviewed…
2015 American Transplant Congress
High Within-Patient Variability in Tacrolimus Levels Is a Predictor of Late Rejection in Young Adult Kidney Transplant Recipients
J. van der Net, P. Harden.
Oxford Transplant Centre / Kidney Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
Introduction: Non-adherence is an important risk factor for late rejection (rejection > 3 months post-transplant) and is the main reason why 17-29 year old kidney…